No abstract

No abstract

No abstract

for infliximab-dyyb, and 35% for infliximab-abdm). Generic small-molecule drugs, however, cost 50% to 80% less than brand-name drugs. ConCluSionS: The US significantly lags in terms of market availability post-exclusivity periods in comparison to that of Europe. The small price discount of biosimilars to reference biologics could have slowed down the uptake of biosimilars in the US market.

S113using HIPAA-compliant methods was successful, giving a sub-sample of linked patients for which both patient-reported data and clinical data can be used to address research questions. Prevalence estimates for linked, non-linked, and the full PaCeR samples were as expected, with the highest prevalence being among those seeking care (linked), and the lowest among those who may or may not be seeking care (non-linked).